These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26568478)

  • 1. Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.
    Kim KK; Han A; Yano N; Ribeiro JR; Lokich E; Singh RK; Moore RG
    Sci Rep; 2015 Nov; 5():15911. PubMed ID: 26568478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.
    Ahsan A; Hiniker SM; Ramanand SG; Nyati S; Hegde A; Helman A; Menawat R; Bhojani MS; Lawrence TS; Nyati MK
    Cancer Res; 2010 Apr; 70(7):2862-9. PubMed ID: 20215522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.
    Kim KK; Kawar NM; Singh RK; Lange TS; Brard L; Moore RG
    Gynecol Oncol; 2011 Jul; 122(1):183-9. PubMed ID: 21529906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.
    Refaat A; Aminullah ; Zhou Y; Kawanishi M; Tomaru R; Abdelhamed S; Shin MS; Koizumi K; Yokoyama S; Saiki I; Sakurai H
    Biochem Biophys Res Commun; 2015 Mar; 458(4):856-61. PubMed ID: 25701783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor.
    Winograd-Katz SE; Levitzki A
    Oncogene; 2006 Nov; 25(56):7381-90. PubMed ID: 16785992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
    Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
    Chan JK; Pham H; You XJ; Cloven NG; Burger RA; Rose GS; Van Nostrand K; Korc M; Disaia PJ; Fan H
    Cancer Res; 2005 Apr; 65(8):3243-8. PubMed ID: 15833856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH; Song YC; Kim SH; Jo H; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells.
    Kuroda H; Takeno M; Murakami S; Miyazawa N; Kaneko T; Ishigatsubo Y
    Lung Cancer; 2010 Jan; 67(1):31-6. PubMed ID: 19375813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
    Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.
    Zwang Y; Yarden Y
    EMBO J; 2006 Sep; 25(18):4195-206. PubMed ID: 16932740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functions of epidermal growth factor receptor in cisplatin response of thyroid cells.
    Muscella A; Urso L; Calabriso N; Vetrugno C; Fanizzi FP; Storelli C; Marsigliante S
    Biochem Pharmacol; 2009 Mar; 77(6):979-92. PubMed ID: 19111676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
    Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
    Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
    Ishitsuka A; Fujine E; Mizutani Y; Tawada C; Kanoh H; Banno Y; Seishima M
    Int J Mol Med; 2014 Oct; 34(4):1169-74. PubMed ID: 25109763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma.
    Kwon J; Yoon HJ; Kim JH; Lee TS; Song IH; Lee HW; Kang MC; Park JH
    Oncol Rep; 2014 Sep; 32(3):1188-92. PubMed ID: 24993015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.